share_log

Altimmune | SC 13G: Statement of acquisition of beneficial ownership by individuals-Millennium Management LLC(5.4%),Millennium Group Management LLC(5.4%), etc.

SEC announcement ·  Mar 5 16:35
Summary by Moomoo AI
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more